Background: To determine the effect of photodynamic therapy (PDT) in chronic central serous chorioretinopathy (CSCR) and to describe fundus autofluorescence (AF) patterns before and after PDT. Methods: Seven eyes of 7 patients with chronic CSCR were included. Patients underwent complete ophthalmic examination and macular optical coherence tomography (OCT) scans were taken. Fluorescein and indocyanine green angiographies and fundus AF images were obtained by Heidelberg Retinal Angiography 2 (HRA2). PDT was performed according to the standard TAP protocol on the site of leakage area and submacular fluid. The mean follow-up period was 5.4 months. Results: Submacular fluid disappeared in all eyes 1 month after PDT and there was no recurrence during the follow-up. Visual acuity increased two or more lines in 5 eyes. Hyperautofluorescence in the area of previous retinal detachment significantly increased in the first month of PDT compared to preoperative findings. After the first month during the follow-up, increased AF in the area of previous retinal elevation returned to the baseline intensity. Conclusion: PDT of CSCR may result with resolution of subretinal fluid and visual improvement. Fundus AF may be an additional tool for monitoring the functional status of retinal pigment epithelium.

1.
Gass JDM: Pathogenesis of disciform detachment of the neuroepithelium. II. Idiopathic central serous chorioretinopathy. Am J Ophthalmol 1967;63:587–615.
2.
Gass JDM: Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment, ed 4. St Louis, Mosby, 1997, vol 1, pp 52–70.
3.
Gilbert CM, Owens SL, Smith PD, Fine SL: Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 1984;68:815–820.
4.
Hussain D, Gass JD: Idiopathic central serous chorioretinopathy. Indian J Ophthalmol 1998;46:131–137.
5.
Costa RA, Scapucin L, Moraes NS, et al: Indocyanine green-mediated photothrombosis as a new technique of treatment for persistent central serous chorioretinopathy. Curr Eye Res 2002;25:287–297.
6.
Berger AR, Olk RJ, Burgess D: Central serous chorioretinopathy in patients over 50 years of age. Ophthalmic Surg 1991;22:583–590.
7.
Jalkh AE, Jabbour N, Avila MP, Trempe CL, Schepens CL: Retinal pigment epithelium decompensation. I. Clinical features and natural course. Ophthalmology 1984;91:1544–1548.
8.
Jalkh AE, Jabbour N, Avila MP, Trempe CL, Schepens CL: Retinal pigment epithelium decompensation. II. Laser treatment. Ophthalmology 1984;91:1549–1553.
9.
Yannuzzi LA, Slakter JS, Kaufman SR, Gupta K: Laser treatment of diffuse retinal pigment epitheliopathy. Eur J Ophthalmol 1992;2:103–114.
10.
Piccolino FC, Eandi C, Ventre L, Longrais RCR, Grignolo FM: Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003;23:752–763.
11.
Taban M, Boyer DS, Thomas EL, Taban M: Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol 2004;137:1073–1080.
12.
Yannuzzi LA, Slakter JS, Gross NE, et al: Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003;23:288–298.
13.
Yoshioka H, Katsume Y: Experimental central serous chorioretinopathy. III. Ultrastructural findings. Jpn J Ophthalmol 1982;26:397–402.
14.
Hall LS, Guyer DR, Yanuzzi LA: Central serous retinopathy; in Guyer DR, Yanuzzi LA, Chang S, Shields JA, Green WR (eds): Retina-Vitreus-Macula. Philadelphia, Saunders, 1999, vol 1, pp 206–216.
15.
Kitagawa K, Nishida S, Ogura Y: In vivo quantitation of autofluorescence in human RPE. Ophthalmologica 1989;199:116–121.
16.
Delori FC, Dorey K, Staurenghi G, Arend O, Goger DG, Weiter JJ: In vivo autofluorescence of the ocular fundus exhibits retinal pigment epithelial lipofuscin characteristics. Invest Ophthalmol Vis Sci 1995;36:718–729.
17.
Von Rückmann A, Fizke FW, Bird AC: Distribution of fundus autofluorescence with scanning laser ophthalmoscope. Br J Ophthalmol 1995;119:543–562.
18.
Von Rückmann A, Fizke FW, Bird AC: Fundus autofluorescence in age-related macular disease imaged with a laser scanning ophthalmoscope. Invest Ophthalmol Vis Sci 1997;38:478–486.
19.
Von Rückmann A, Fizke FW, Fan J, Halfyard A, Bird AC: Abnormalities of fundus autofluorescence in central serous retinopathy. Am J Ophthalmol 2002;133:780–786.
20.
Eandi CM, Ober M, Iranmanesh R, Peiretti E, Yannuzzi LA: Acute central serous chorioretinopathy and fundus autofluorescence. Retina 2005;25:989–993.
21.
Framme C, Walter A, Gabler B, Roider J, Sachs G, Gabel VP: Fundus autofluorescence in acute and chronic recurrent central serous chorioretinopathy. Acta Ophthalmol Scand 2005;83:161–167.
22.
Holz PG, Schuett F, Kopitz J, et al: Inhibition of lysosomal degradative functions in RPE cells by a retinoid of component of lipofuscin. Invest Ophthalmol Vis Sci 1999;40:737–743.
23.
Framme C, Roider J: Immediate and long-term changes of fundus autofluorescence in continuous wave laser lesions of the retina. Ophthalmic Surg Lasers Imaging 2004;35:131–138.
24.
Feeney-Burns L, Hildebrand ES, Eldridge S: Ageing human RPE: morphometric analysis of macular, equatorial and peripheral cells. Invest Ophthalmol Vis Sci 1984;25:195–200.
25.
Woodburn KW, Engelman CJ, Blumenkranz MS: Photodynamic therapy for choroidal neovascularization. Retina 2002;22:391–405.
26.
Schotzer-Schrehardt U, Viestenz A, Naumann GOH, et al: Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 2002;240:748–757.
27.
Schimdt-Erfurth U, Michels S, Barbazetto I, Laqua H: Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 2002;43:830–841.
28.
Husain D, Miller JW, Michand N, et al: Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol 1996;114:978–985.
29.
Haimovici R, Kramer M, Miller JW, et al: Localization of lipoprotein-derived benzoporphyrin in the rabbit eye. Curr Eye Res 1997;16:83–90.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.